Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCigna Kalbitor Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    ModifiedCignaPolicy IP0336

    Hereditary Angioedema - Kalbitor

    Customize your policy alerts

    Sign up for Cigna Policy IP0336 alerts

    Get alerted when Policy IP0336 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Kalbitor (ecallantide) subcutaneous injection for acute attacks of hereditary angioedema due to C1-inhibitor deficiency.

    Policy Summary
    PayerCigna
    PolicyHereditary Angioedema - Kalbitor
    Policy CodePolicy IP0336
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewNov 5, 2026
    Next Review DateNot specified
    Key ActionSubmit documentation showing functional C1-INH below 50% of normal and lower-than-normal baseline serum C4 for initial therapy.
    SourceLink
    POLICY UPDATE CHANGES

    Coverage was revised to specify hereditary angioedema due to C1-inhibitor deficiency for acute attacks.

    Low functional C1-INH protein and lower-than-normal baseline serum C4 are now required for diagnostic confirmation.

    The requirement for a confirmed pathogenic variant in specified genes was removed.

    Coverage criteria now require confirmed HAE type I or type II and expressly exclude HAE with normal C1-INH.

    The requirement for low baseline C1-inhibitor antigenic levels was removed.

    The requirement prohibiting concomitant use with other FDA-approved acute HAE treatments was removed.

    A specialist requirement was added and clarified.

    Criteria for previous Kalbitor treatment were added.

    Preferred-product criteria were revised by plan type.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1 yearApproval duration
    30 mgMaximum dose
    Twice dailyMaximum frequency
    I or IIQualifying HAE types
    IIINonqualifying HAE type

    Coverage Criteria

    Acute HAE Attacks Due to C1-INH Deficiency

    Kalbitor is covered for 1 year for treatment of acute hereditary angioedema (HAE) attacks due to C1 inhibitor (C1-INH) deficiency when the patient meets ONE of the following pathways:

    Initial therapy — ALL of the following

    • ALL of the following

      • HAE type I or type II confirmed by BOTH criteria

        • Functional C1-INH protein is low at baseline (< 50% of normal), as defined by laboratory reference values. [Documentation required]< 50% of normal
        • Serum C4 level is lower than normal at baseline, as defined by laboratory reference values. [Documentation required]
      • The medication is prescribed by, or in consultation with, an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.
      • Preferred product criteria — ONE of the following

        • Employer Plan: Patient is less than 18 years of age.
        • Employer Plan: Patient has previously treated an acute HAE attack with Kalbitor.
        • Employer Plan: Patient has tried generic icatibant.
        • Individual and Family Plan: Patient is less than 18 years of age.
        • Individual and Family Plan: Patient has previously treated an acute HAE attack with Kalbitor.
        • Individual and Family Plan: Patient has tried generic icatibant or Sajazir.

    Previous treatment with Kalbitor — ALL of the following

    • Patient has a diagnosis of HAE type I or type II. [Documentation required]
    • According to the prescriber, the patient has had a favorable clinical response with Kalbitor treatment.

      Examples include decreased duration of HAE attacks, quick onset of symptom relief, complete resolution of symptoms, or decreased acute attack frequency or severity.

    • The medication is prescribed by, or in consultation with, an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.

    Dosing

    Coverage is limited to the following dose and administration frequency:

    ALL of the following

    • Administer up to a maximum dose of 30 mg per injection subcutaneously.<= 30 mg per injection
    • Administer no more frequently than twice daily.<= 2 times daily

    A diagnosis of HAE with normal C1-INH, also known as HAE type III, does not satisfy the diagnostic requirement for coverage.

    Kalbitor prophylaxis is not covered. Data are not available, and Kalbitor is not indicated for prophylaxis of HAE attacks.

    Coverage is limited to HAE type I or type II due to C1-INH deficiency; HAE with normal C1-INH, also known as HAE type III, is outside the covered indication.

    Kalbitor for uses other than treatment of covered acute HAE attacks due to C1-INH deficiency is considered not medically necessary, including uses not supported by the covered indication.

    Coding and Clinical Parameters

    Considered Medically Necessary HCPCS CodeHCPCSCovered
    J1290Injection, ecallantide, 1 mg
    Functional C1-INH protein
    TestFunctional C1-INH protein
    Baseline thresholdLess than 50% of normal
    DocumentationLaboratory reference values are required
    Serum C4
    TestSerum C4
    Baseline findingLower than normal
    Reference standardAccording to laboratory reference values

    Provider Requirements and Decision Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for benefit coverage of Kalbitor. Approval is recommended only when the applicable coverage criteria and dosing requirements are met.

    Prior Authorization

    Specialist Involvement and Approval Term

    Kalbitor approval is available for 1 year when coverage criteria are met. For both initial and continuation therapy, the medication must be prescribed by or in consultation with an allergist/immunologist or another physician who specializes in treating HAE or related disorders.

    • A patient currently receiving Kalbitor who previously satisfied initial-therapy criteria may be reviewed under continuation criteria.
    • If prior Kalbitor approval was not obtained through the Coverage Review Department, initial-therapy criteria apply.
    Note

    Clinical Background

    Kalbitor (ecallantide) is a plasma kallikrein inhibitor indicated for the treatment of acute hereditary angioedema attacks in patients aged 12 years and older. Because serious hypersensitivity reactions, including anaphylaxis, may occur, Kalbitor must be administered by a healthcare professional with appropriate medical support for anaphylaxis and HAE. HAE type I and type II are associated with deficient or dysfunctional C1-INH, whereas HAE with normal C1-INH has limited evidence for Kalbitor use.

    Definitions

    HAE due to C1-INH deficiency
    Qualifying subtypesHAE type I or type II due to C1-INH deficiency
    Functional C1-INH confirmationLess than 50% of normal at baseline
    Serum C4 confirmationLower than normal at baseline according to laboratory reference values
    HAE with normal C1-INH
    ConditionHAE with normal C1-INH
    Alternate terminologyHAE type III
    Coverage statusDoes not satisfy the diagnostic requirement for coverage

    Initial Therapy

    Initial Therapy

    Approve for 1 year when all initial-therapy requirements and the applicable preferred-product criterion are met.

    ALL initial-therapy requirements

    • Diagnostic confirmation: Functional C1-INH protein is low at baseline.< 50% of normal

      Documentation required.

    • Diagnostic confirmation: Serum C4 is lower than normal at baseline according to laboratory reference values.

      Documentation required.

    • Applicable preferred-product criterion

    Continuation Therapy

    Continuation Therapy

    Approve for 1 year when the patient has previously treated acute HAE attacks with Kalbitor and meets all continuation requirements.

    ALL continuation-therapy requirements: Patient has previously treated acute HAE attacks with Kalbitor; has HAE type I or type II; according to the prescriber, has had a favorable clinical response with Kalbitor; and Kalbitor is prescribed by or in consultation with an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.

    A favorable response may include decreased attack duration, quick onset of symptom relief, complete resolution of symptoms, or decreased HAE acute attack frequency or severity.

    Previous Kalbitor Treatment

    Continuation authorization applies when the patient has treated previous acute HAE attacks with Kalbitor.

    Previous Kalbitor treatment: Patient has previously treated acute HAE attacks with Kalbitor, has HAE type I or type II, has had a favorable clinical response according to the prescriber, and receives Kalbitor through an allergist/immunologist or a physician who specializes in the treatment of HAE or related disorders.

    Preferred Product and Step Requirements

    ProductPreferred-product criteria
    Kalbitor (ecallantide subcutaneous injection)Patient meets one of the following: less than 18 years of age; previously treated an acute HAE attack with Kalbitor; or tried generic icatibant.
    ProductPreferred-product criteria
    Kalbitor (ecallantide subcutaneous injection)Patient meets one of the following: less than 18 years of age; previously treated an acute HAE attack with Kalbitor; or tried generic icatibant or Sajazir.

    Quantity and Administration Limits

    Kalbitor (ecallantide)
    ProductKalbitor (ecallantide)
    Maximum doseUp to 30 mg per injection
    Administration routeSubcutaneous injection
    Maximum frequencyNo more frequently than twice daily

    Administration Site and Safety

    Billing Rule

    Administer in an appropriately supported office setting

    Kalbitor must be administered by a healthcare professional with appropriate medical support to manage potential anaphylaxis and HAE.

    Policy Summary
    PayerCigna
    PolicyHereditary Angioedema - Kalbitor
    Policy CodePolicy IP0336
    Change TypeModified
    Effective DateNov 15, 2026
    Last ReviewNov 5, 2026
    Next Review DateNot specified
    Key ActionSubmit documentation showing functional C1-INH below 50% of normal and lower-than-normal baseline serum C4 for initial therapy.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ParametersProvider Requirements and Decision RisksClinical BackgroundDefinitionsInitial TherapyContinuation TherapyPreferred Product and Step RequirementsQuantity and Administration LimitsAdministration Site and Safety
    Kalbitor dose
    Maximum dose30 mg per injection
    RouteSubcutaneous administration
    FrequencyNo more frequently than twice daily

    HAE Specialist Involvement

    Because HAE diagnosis, treatment evaluation, and monitoring require specialized expertise, the prescriber or consulting physician must specialize in HAE or related disorders.

    • An allergist/immunologist qualifies when involved in prescribing or consultation.
    • Document the specialist’s involvement in the request.
    Note

    Previous Kalbitor Treatment

    Patients previously treated with Kalbitor for acute HAE attacks are subject to separate continuation-therapy requirements unless they lack prior approval through the Coverage Review Department.

    • Document HAE type I or type II.
    • The prescriber must report a favorable clinical response to Kalbitor, such as shorter attacks, faster symptom relief, complete symptom resolution, or reduced attack frequency or severity.
    • The medication must be prescribed by or in consultation with an allergist/immunologist or physician specializing in HAE or related disorders.
    Step Therapy

    Preferred Product Criteria

    The preferred-product requirement depends on the member’s plan type. For Kalbitor, the patient must meet at least one applicable product criterion.

    • Employer plans: patient is younger than 18 years; has previously treated an acute HAE attack with Kalbitor; or has tried generic icatibant.
    • Individual and family plans: patient is younger than 18 years; has previously treated an acute HAE attack with Kalbitor; or has tried generic icatibant or Sajazir.
    • A previous trial of any icatibant product may satisfy the applicable trial requirement.
    Documentation Required

    Required Supporting Documentation

    Submit documentation when the criteria identify it as required. Records must contain patient-specific identifying information.

    • Chart notes
    • Laboratory tests and medical test results
    • Claims records
    • Prescription receipts
    • Other information identified in the applicable criteria
    Documentation Required

    Diagnostic and Response Documentation

    For initial therapy, document the baseline laboratory evidence supporting HAE due to C1-INH deficiency. For continuation therapy, document the patient’s favorable clinical response to Kalbitor.

    • Functional C1-INH protein is below 50% of normal at baseline, according to laboratory reference values.
    • Serum C4 is below normal at baseline, according to laboratory reference values.
    • Examples of favorable response include decreased attack duration, rapid symptom relief, complete symptom resolution, or reduced attack frequency or severity.
    Documentation Required

    HAE Subtype and Diagnostic Confirmation

    Document that the patient has HAE type I or type II and provide the specified diagnostic confirmation for the requested indication.

    • Initial therapy requires both low baseline functional C1-INH and lower-than-normal baseline serum C4, as defined by laboratory reference values.
    • Continuation therapy requires documentation of HAE type I or type II.
    • The policy no longer relies on confirmation of a pathogenic SERPING1, F12, ANGPT1, PLG, or KNG1 gene variant.

    Unsupported block type: denial_riskเหม

    Unsupported block type: denial_risk้า

    Unsupported block type: denial_risk

    Denial Risk

    Nonqualifying HAE Subtype

    HAE with normal C1-INH, also known as HAE type III, does not satisfy the policy’s diagnostic requirement for Kalbitor coverage.

    • The covered diagnosis requires HAE type I or type II due to C1-INH deficiency.
    • Normal-C1-INH disease does not qualify under the clarified diagnostic criteria.
    Favorable clinical response
    Attack durationDecreased duration of HAE attacks
    Symptom reliefQuick onset of symptom relief
    Symptom resolutionComplete resolution of symptoms
    Attack frequency or severityDecreased frequency or severity of acute HAE attacks
    HAE with normal C1 inhibitor
    ConditionHAE with normal C1 inhibitor
    Alternate terminologyHAE type III
    Diagnostic statusDoes not satisfy the diagnostic requirement for coverage
    Employer Plans:
    Patient meets one of the following: is less than 18 years old; has previously treated an acute HAE attack with Kalbitor; or has tried generic icatibant.
  1. Individual and Family Plans: Patient meets one of the following: is less than 18 years old; has previously treated an acute HAE attack with Kalbitor; or has tried generic icatibant or Sajazir.
  2. Initial Kalbitor Authorization

    Initial Kalbitor authorization requires a qualifying HAE diagnosis and specialist involvement.

    Initial authorization requirements

    • Diagnostic confirmation: Functional C1-INH protein is low at baseline.< 50% of normal

      HAE with normal C1-INH, also known as HAE type III, does not satisfy this requirement.

    • Diagnostic confirmation: Serum C4 is lower than normal at baseline according to laboratory reference values.

    HAE with normal C1-INH, also known as HAE type III, does not satisfy the diagnostic requirement.